Companion Diagnostics Market: Key Trends and Developments
Introduction to Companion Diagnostics Market:
Companion
diagnostics are medical tests that are used to identify the patients
who may benefit from a particular therapy, and to identify those patients who
are more likely to respond to a given therapy. Companion diagnostics are used
to select patients who are likely to benefit from a given treatment, and to
identify those who are more likely to experience adverse effects from the same
treatment. Companion diagnostics can also be used to monitor the effectiveness
of a given treatment, and to identify potential drug-drug interactions.
Companion diagnostics are rapidly becoming an essential part of personalized medicine
and are an important tool for improving patient outcomes.
The report "Companion Diagnostics Market by Product
(Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC),
Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User
(Pharma Companies, CROs), Region - Global Forecast to 2026", the global
companion diagnostics market is projected to reach USD 9.9 billion by 2026 from
USD 5.5 billion in 2021, at a CAGR of 12.6%.
Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681
Overview of Companion Diagnostics:
Companion diagnostics are diagnostic tests that are used in
conjunction with therapeutic treatments to ensure that the patient is receiving
the most effective and safe treatment for their particular condition. These
tests analyze genetic, biomarker, and/or clinical data to determine the best
course of action for the patient. Companion diagnostics are increasingly being
used in oncology and personalized medicine to tailor treatments to individual
patients, with the aim of improving health outcomes and reducing costs. These
diagnostics are also being used to detect and monitor drug resistance, predict
adverse drug reactions, and guide the selection of personalized cancer
treatments.
Market Dynamics of Companion Diagnostics:
1. Increasing Demand for Personalized Medicine: The demand
for personalized medicine is growing rapidly, driven by the need to provide
tailored treatments for patients. As companion diagnostics can provide
personalized medical information on individual patients, they are increasingly
being used to develop more effective treatments.
2. Advances in Technology: Advances in technology, such as
next-generation sequencing, have enabled the development of more sophisticated
and accurate companion diagnostics. This has increased their popularity among
healthcare providers and pharmaceutical companies, as they can provide more
detailed information about a patient’s condition.
3. Regulatory Requirements: Regulatory requirements are an
important factor driving the growth of the companion diagnostics market.
Governments around the world are increasingly mandating the use of companion
diagnostics in order to ensure the safety and efficacy of new drugs and
treatments.
4. High Cost of Diagnostics: The cost of companion
diagnostics can be high, making it a barrier to market growth. The high cost of
the technology and tests can limit the market’s potential to expand.
5. Low Awareness: Low levels of awareness about companion
diagnostics is another major factor that can limit its market growth. Many
patients and healthcare providers are not yet aware of the benefits of using
companion diagnostics, which can limit its adoption.
Competitive Landscape of Companion Diagnostics Market:
The global companion diagnostics market is moderately
competitive owing to the presence of several established players and the entry
of new players. These players are actively launching new products and
introducing innovative technologies to remain competitive in the market. This
has been leading to the expansion of the global companion diagnostics market.
The major players operating in this market are F. Hoffmann-La
Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V.
(Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US),
Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA
(France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova
Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex
Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US),
NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China),
Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden),
Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).
Market Segmentation:
By Product & Service
·
Assays, Kits & Reagents
·
Software & Services
By Technology
·
Polymerase Chain Reaction
·
Next-generation Sequencing
·
In Situ Hybridization
·
Immunohistochemistry
·
Other Technologies
By Indication
·
Cancer `
o
Lung Cancer
o
Breast Cancer
o
Blood Cancer
o
Colorectal Cancer
o
Other Cancer Types
·
Neurological Disorders
·
Cardiovascular Diseases
·
Infectious Diseases
·
Other Indications
By End User
·
Pharmaceutical & Biopharmaceutical Companies
·
Reference Laboratories
·
Contract Research Organizations
·
Other End Users
By Region:
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Regional Analysis:
The global companion diagnostics market is estimated to
register a CAGR of 12.6% during the forecast period. The market is segmented
into North America, Europe, Asia Pacific, Latin America, and the Middle East
& Africa. Among these, North America is expected to dominate the global
companion diagnostics market, owing to the presence of leading players in the
region, rapidly developing technology, and higher healthcare expenditure.
Europe is anticipated to hold the second-largest share of
the global companion diagnostics market, due to the increasing emphasis on
personalized medicine and the increasing adoption of advanced technologies.
Asia Pacific is projected to register the fastest growth
rate during the forecast period, owing to the increasing government initiatives
for healthcare development and the growing awareness about innovative
technologies.
Recent Developments:
·
In May 2021, Qiagen N.V. (Germany) expanded the
therascreen KRAS Kit.
·
In April 2019, Roche Diagnostics (Switzerland)
acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s
broad portfolio of molecular diagnostics solutions with a wide range of assays
for infectious diseases, such as identifying SARS-CoV-2 variants.
Key Questions Answered by the Report:
• What are the current and future trends in the global
companion diagnostics market?
• How is the global companion diagnostics market segmented?
• What are the major drivers, challenges, and opportunities
in the global companion diagnostics market?
• What is the competitive landscape of the global companion
diagnostics market?
• What are the key strategies adopted by major players in
the global companion diagnostics market?
• What is the estimated market size and growth rate of the
global companion diagnostics market for the forecast period?
Conclusion:
The companion diagnostics market is set to experience rapid
growth in the next five years. This growth is being driven by the rising
prevalence of chronic diseases and the increasing demand for personalized
medicine. Additionally, the development of new technologies and the increasing
number of clinical trials for companion diagnostics are expected to further
boost market growth. The increasing collaboration between pharmaceutical companies
and diagnostic companies is also expected to play a role in the growth of the
market.
Related Articles:
https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html
https://www.marketsandmarkets.com/PressReleases/companion-diagnostics.asp
https://www.marketsandmarkets.com/ResearchInsight/companion-diagnostics-market.asp
Comments
Post a Comment